The 2021-2022 Omnibus Solicitation is open to small business researchers and entrepreneurs working on innovative technologies in translational sciences. Standard deadlines apply. The next due dates are January 5, and April 5, 2022, at 5:00 pm ET.
NCATS is particularly interested in applications that address research areas relevant to any stage of translation, from target validation through pre-clinical and clinical evaluation, to intervention implementation and dissemination, including:
Please note: NCATS will not accept SBIR/STTR applications that include clinical trials under the current Omnibus Solicitation
The National Center for Advancing Translational Science (NCATS) is participating in the NIH Applicant Assistance Program (AAP), a free, 10-week program that helps small businesses apply for Phase I SBIR or STTR funding. AAP provides participants with a dedicated coach with expertise in preparing NIH small business grants and services such as application needs assessment, mentoring, application preparation support, and application review. The program supports the preparation of SBIR or STTR Phase I grants only.
The NIH will begin accepting applications for the April 5, 2022 SBIR/STTR application cycle on Monday November 15, 2021, when the AAP Application Portal opens. The deadline for applications is Friday, December 10, 2021, at 5:00 p.m. ET. Selected participants will be notified in January.
Who Is Eligible?
New applicants, who have not previously applied to the SBIR/STTR program, and do not have an application in review now are eligible to participate in the AAP. Applicants from underrepresented small businesses, especially minority- and women-owned companies, are strongly encouraged to apply.
The Bristol Myers Squibb Foundation and National Medical Fellowships have created the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program to increase diversity in clinical trials. The initiative is comprised of a Career Development Program for early-stage clinical investigators and a Clinical Investigator Pipeline Program for rising second-year medical students.
As part of UC San Diego Altman Clinical and Translational Research Institute (ACTRI), the KL2 grant mechanism is an institutional equivalent of a K23, K01, or K08 award for junior faculty. The KL2 also provides didactic opportunities through ACTRI's CREST program and a mentored research experience. Successful applicants will receive up to three years of support pending good progress.
Applications due February 25, 2022. Download the Funding Opportunity Announcement
For more detailed information, see the KL2 website.